-
Privacy-Preserving Multi-Center Differential Protein Abundance Analysis with FedProt
Authors:
Yuliya Burankova,
Miriam Abele,
Mohammad Bakhtiari,
Christine von Törne,
Teresa Barth,
Lisa Schweizer,
Pieter Giesbertz,
Johannes R. Schmidt,
Stefan Kalkhof,
Janina Müller-Deile,
Peter A van Veelen,
Yassene Mohammed,
Elke Hammer,
Lis Arend,
Klaudia Adamowicz,
Tanja Laske,
Anne Hartebrodt,
Tobias Frisch,
Chen Meng,
Julian Matschinske,
Julian Späth,
Richard Röttger,
Veit Schwämmle,
Stefanie M. Hauck,
Stefan Lichtenthaler
, et al. (6 additional authors not shown)
Abstract:
Quantitative mass spectrometry has revolutionized proteomics by enabling simultaneous quantification of thousands of proteins. Pooling patient-derived data from multiple institutions enhances statistical power but raises significant privacy concerns. Here we introduce FedProt, the first privacy-preserving tool for collaborative differential protein abundance analysis of distributed data, which uti…
▽ More
Quantitative mass spectrometry has revolutionized proteomics by enabling simultaneous quantification of thousands of proteins. Pooling patient-derived data from multiple institutions enhances statistical power but raises significant privacy concerns. Here we introduce FedProt, the first privacy-preserving tool for collaborative differential protein abundance analysis of distributed data, which utilizes federated learning and additive secret sharing. In the absence of a multicenter patient-derived dataset for evaluation, we created two, one at five centers from LFQ E.coli experiments and one at three centers from TMT human serum. Evaluations using these datasets confirm that FedProt achieves accuracy equivalent to DEqMS applied to pooled data, with completely negligible absolute differences no greater than $\text{$4 \times 10^{-12}$}$. In contrast, -log10(p-values) computed by the most accurate meta-analysis methods diverged from the centralized analysis results by up to 25-27. FedProt is available as a web tool with detailed documentation as a FeatureCloud App.
△ Less
Submitted 21 July, 2024;
originally announced July 2024.
-
Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing
Authors:
Andreas Maier,
Michael Hartung,
Mark Abovsky,
Klaudia Adamowicz,
Gary D. Bader,
Sylvie Baier,
David B. Blumenthal,
Jing Chen,
Maria L. Elkjaer,
Carlos Garcia-Hernandez,
Mohamed Helmy,
Markus Hoffmann,
Igor Jurisica,
Max Kotlyar,
Olga Lazareva,
Hagai Levi,
Markus List,
Sebastian Lobentanzer,
Joseph Loscalzo,
Noel Malod-Dognin,
Quirin Manz,
Julian Matschinske,
Miles Mee,
Mhaned Oubounyt,
Alexander R. Pico
, et al. (14 additional authors not shown)
Abstract:
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining…
▽ More
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.
△ Less
Submitted 4 July, 2023; v1 submitted 24 May, 2023;
originally announced May 2023.
-
Flimma: a federated and privacy-preserving tool for differential gene expression analysis
Authors:
Olga Zolotareva,
Reza Nasirigerdeh,
Julian Matschinske,
Reihaneh Torkzadehmahani,
Tobias Frisch,
Julian Späth,
David B. Blumenthal,
Amir Abbasinejad,
Paolo Tieri,
Nina K. Wenke,
Markus List,
Jan Baumbach
Abstract:
Aggregating transcriptomics data across hospitals can increase sensitivity and robustness of differential expression analyses, yielding deeper clinical insights. As data exchange is often restricted by privacy legislation, meta-analyses are frequently employed to pool local results. However, if class labels are inhomogeneously distributed between cohorts, their accuracy may drop. Flimma (https://e…
▽ More
Aggregating transcriptomics data across hospitals can increase sensitivity and robustness of differential expression analyses, yielding deeper clinical insights. As data exchange is often restricted by privacy legislation, meta-analyses are frequently employed to pool local results. However, if class labels are inhomogeneously distributed between cohorts, their accuracy may drop. Flimma (https://exbio.wzw.tum.de/flimma/) addresses this issue by implementing the state-of-the-art workflow limma voom in a privacy-preserving manner, i.e. patient data never leaves its source site. Flimma results are identical to those generated by limma voom on combined datasets even in imbalanced scenarios where meta-analysis approaches fail.
△ Less
Submitted 23 November, 2020; v1 submitted 30 October, 2020;
originally announced October 2020.
